BIO's Industry Analysis team has released its first report in a new series on the state of innovation in highly prevalent chronic diseases. The new series of reports will dig deeper into a previously observed phenomenon: less venture dollars are heading into chronic diseases. BIO’s previous…

This week the Patient and Health Advocacy Summit concluded its sixth consecutive year, bringing hundreds of patient advocates and policymakers together to engage on important issues facing the patient community.  This year’s Summit featured a new Personalized Medicine Workshop that offered a unique…

Alarm bells have been sounding for some time that deadly infections are developing resistance to the drugs available to treat them. For decades, new drugs were deployed when existing drugs proved insufficient, keeping the problem at bay. But economic realities may block further advances, creating a…

A recent article by Brandon McFadden in The Conversation dove into the food labeling craze, explaining how labels can often mislead. The food labeling craze coupled with banner headlines about the dangers of gluten, genetically modified organisms (GMOs) and hormones are leading to increasingly…

Deborah Goldberg’s op-ed to The Sacramento Bee recounts her three-year battle with colon cancer. She also worries that California legislators may unwittingly jeopardize future innovation and harm patients in the long run, through Senate Bill 17. The proposed legislation purports to address…

World Mosquito Day fell this past Sunday, providing an opportunity to highlight biotechnology's contributions to fighting mosquito-borne disease across the world. BIO President and CEO Jim Greenwood penned an op-ed in The Hill on the "friendly mosquito," a biotech solution to life-threatening…

Breaking all previous records, BIO 2017 hosted over 41,400 partnering meetings during this year’s event. Facilitated by BIO’s unique One-on-One Partnering™ system, these invaluable connections form the foundation of innovative industry collaborations and scientific breakthroughs. That word…

  With over 1,800 exhibitors at BIO2017, there is truly something for everyone.  From a puppy, to pie to paracite-free mobile labs! First, and most fluffy, is Baxter, the cloned puppy.  Baxter is an 18 week old toy poodle.  The original toy poodle is still alive.  Baxter is a nearly…

John Maraganore, CEO of Cambridge-based Alnylam Pharmaceuticals, begins his chairmanship of BIO this morning when outgoing Chairman Ron Cohen passes him the gavel after two successful years at the helm. Maraganore is a beloved figure in the Cambridge  biotech community. He has worked in the same…

Five years ago, during the height of his leadership, then-Prime Minister David Cameron of the United Kingdom took on the world’s “collective denial [of] one of the greatest challenges of our time … one that steals lives and tears at the hearts of families, but that relative to its impact, is hardly…